Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Ovis aries | Cyclooxygenase-1 | Starlite/ChEMBL | References |
Ovis aries | Cyclooxygenase-2 | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.72 nM | Inhibition of ovine COX2 assessed as inhibition of PGF2a formation after 20 mins by Ellman's method | ChEMBL. | 20387815 |
IC50 (binding) | = 13880 nM | Inhibition of ovine COX1 assessed as inhibition of PGF2a formation after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 16 % | Inhibition of ovine COX1 assessed as inhibition of PGF2a formation at 1 uM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 38 % | Inhibition of ovine COX1 assessed as inhibition of PGF2a formation at 10 uM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 50 % | Inhibition of ovine COX2 assessed as inhibition of PGF2a formation at 0.001 uM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 52 % | Inhibition of ovine COX1 assessed as inhibition of PGF2a formation at 100 uM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 78 % | Inhibition of ovine COX2 assessed as inhibition of PGF2a formation at 0.01 uM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 83 % | Inhibition of ovine COX2 assessed as inhibition of PGF2a formation at 100 nM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 86 % | Inhibition of ovine COX2 assessed as inhibition of PGF2a formation at 10 uM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Inhibition (binding) | = 88 % | Inhibition of ovine COX2 assessed as inhibition of PGF2a formation at 1 uM after 20 mins by Ellman's method | ChEMBL. | 20387815 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.